GZYJPCO(SH:603058)2023-03-30 16:00Dividend Distribution - The company plans to distribute a cash dividend of 2.5 yuan (pre-tax) for every 10 shares, totaling approximately 103,674,964.50 yuan for the year 2022[6]. - The cash dividend distribution date is set for September 30, 2022, with the record date being September 29, 2022[6]. - The company does not plan to issue new shares or convert capital reserves into share capital in the current profit distribution[6]. - The company’s cash dividends are contingent upon achieving positive distributable profits and receiving an unqualified audit opinion on financial reports[138]. - The company implements an active dividend distribution policy, prioritizing cash dividends, which should not be less than 20% of the distributable profit for the year[138]. Financial Performance - The company achieved a total revenue of RMB 653.34 million in 2022, representing a year-on-year increase of 49.86%[23]. - Net profit attributable to shareholders decreased by 72.54% to RMB 37.78 million, while the net profit after deducting non-recurring gains and losses increased by 253.55% to RMB 82.73 million[23]. - Operating cash flow increased by 173.09% to RMB 100.23 million, driven by significant growth in sales revenue[25]. - The company's weighted average return on equity decreased by 8.37 percentage points to 3.41%[25]. - Basic earnings per share fell to RMB 0.0911, a decrease of 72.39% compared to the previous year[24]. Revenue Breakdown - Sales revenue from cigarette labels increased by 54.35%, and sales from medical cannabis in Australia surged by 2084.95%[25]. - The revenue from the cigarette label business was 460.47 million yuan, up 54.35% year-on-year, while the wine label business revenue reached 109.08 million yuan, growing by 15.81%[32]. - In the medical cannabis sector, the company’s subsidiary TB achieved sales revenue of 8.2936 million AUD (approximately 38.70451 million yuan), a year-on-year increase of 2084.95%[51]. Assets and Liabilities - The total assets of the company at the end of 2022 were RMB 1.76 billion, an increase of 4.82% from the previous year[23]. - The company reported a net asset attributable to shareholders of RMB 1.05 billion, down 4.39% from the previous year[23]. - The company’s equity attributable to the parent company was 1.05 billion yuan, a decrease of 4.39% from the beginning of the reporting period[61]. Research and Development - The company invested 35,247,549.52 yuan in R&D, an increase of 13.56% year-on-year, and developed a total of 240 new product samples, with 70 products entering production[35]. - The company developed and sampled 50 new cigarette label products in 2022, with 7 products entering production[60]. - For wine label products, the company developed and sampled 174 products, with 50 products entering production[60]. Market Expansion - The company plans to continue expanding its product offerings and market presence, particularly in the medical cannabis sector[25]. - The company is actively pursuing opportunities in the industrial hemp market, which has shown significant growth potential, particularly in Australia[42]. - The company is exploring the development of industrial hemp applications, with a focus on plant-based protein and hemp core materials, aiming to expand into the consumer goods and health industries[37]. Corporate Governance - The company has established a comprehensive governance structure to protect the rights of all shareholders, especially minority shareholders[113]. - The board of directors consists of three members, all of whom are independent directors, ensuring compliance with legal requirements[114]. - The company has not faced any penalties from securities regulatory agencies in the past three years[125]. Environmental Responsibility - The company invested 930,000 RMB in environmental protection during the reporting period[150]. - The company effectively managed wastewater, with all production wastewater being recycled and treated, ensuring compliance with national standards[152]. - The company implemented measures to control emissions of VOCs and other pollutants, with all monitored emissions below regulatory limits[153]. Shareholder Structure - The largest shareholder, Guizhou Yongji Holdings Co., Ltd., holds 172,566,200 shares, representing 41.18% of the total shares, with 84,557,400 shares pledged[199]. - The total number of ordinary shareholders increased from 14,117 to 14,570 during the reporting period[197]. - The top ten shareholders include a mix of corporate and individual investors, with the largest individual shareholder, Deng Weijia, holding 22,000,000 shares, or 5.25%[199]. Risk Management - The company is facing risks from raw material price fluctuations, with direct materials accounting for approximately 70% of its operating costs[108]. - The company is closely monitoring exchange rate fluctuations, particularly between the RMB and AUD, to manage foreign exchange risk[111]. - The company is facing intensified competition in the tobacco industry, leading to potential price reductions and profit margin compression[110].